<DOC>
	<DOCNO>NCT00353015</DOCNO>
	<brief_summary>Primary Objective : 1 . Assess clinical activity define response rate irinotecan cisplatin untreated patient metastatic unresectable high grade neuroendocrine carcinoma gastrointestinal tract . Secondary Objective : 1 . To assess safety profile irinotecan cisplatin untreated patient metastatic unresectable high grade neuroendocrine carcinoma gastrointestinal tract .</brief_summary>
	<brief_title>Irinotecan Cisplatin High Grade Neuroendocrine Carcinoma Gastrointestinal Tract</brief_title>
	<detailed_description>Both irinotecan carboplatin drug commonly use treat cancer . Before treatment start , patient blood test ( around 4 teaspoon ) urine test . Patients chest X-ray , electrocardiogram ( ECG-a test measure electrical activity heart ) , compute tomography ( CT ) scan . Women able child must negative blood pregnancy test . During study , patient receive irinotecan cisplatin vein 4 hour , week 2 week . This follow 7 day treatment give . This 3 week period call cycle . Cycles repeat unless tumor continue grow . During treatment , patient follow-up visit every 3 week check side effect status disease . The follow-up visit may either local doctor study doctor . However , visit study doctor schedule least every 9 week . If disease get bad experience intolerable side effect , take study . This investigational study . Both irinotecan cisplatin FDA approve commercially available . Around 36 patient participate study . All patient enrol M.D . Anderson .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>1 . Histologic diagnosis high grade ( poorly differentiate , small cell ) gastrointestinal neuroendocrine carcinoma . 2 . High grade neuroendocrine carcinoma unknown primary site ( pulmonary primary exclude ) . 3 . Metastatic unresectable disease . 4 . Measurable disease . 5 . Informed consent . 6 . Zubrod performance status 0 1 . 7 . Adequate bone marrow function ( define absolute neutrophil count [ ANC ] &gt; = 1500 , platelet count [ PLT ] &gt; = 100,000 hemoglobin [ Hgb ] &gt; = 10 ) . 8 . Adequate hepatic function bilirubin &lt; = 2.0 mg/dl , aspartate aminotransferase ( AST SGOT ) alanine aminotransferase ( ALT SGPT ) &lt; = 2.5 time upper limit normal , unless cause liver metastasis . If cause metastasis , SGPT SGOT &lt; = 5 time upper limit normal . 9 . Adequate renal function define serum creatinine &lt; = 1.5 mg/dl . 10 . Fertile patient partner must practice appropriate contraceptive method study . 11 . Recovered recent surgery . One week must elapse time minor surgery 3 week major surgery . 1 . Patients prior systemic chemotherapy ineligible . 2 . Other concurrent chemotherapy , immunotherapy , radiotherapy . 3 . Patients brain metastasis eligible . Patients history seizure ineligible . Patients receive phenytoin , phenobarbital , antiepileptic prophylaxis ineligible . 4 . Patients New York Heart Association ( NYHA ) Class III IV heart disease eligible well patient history angina , myocardial infarction , congestive heart failure within six month . 5 . Pregnant lactating woman . All woman child bear potential must negative pregnancy test prior entry study . All patient child bear potential must advise importance avoid pregnancy use appropriate method contraception participate investigational trial . 6 . Patients serious intercurrent infection , nonmalignant medical illness uncontrolled whose control may jeopardize complication therapy , ineligible . 7 . Patients psychiatric disorder render incapable complying requirement protocol ineligible . 8 . Patients serum calcium &gt; 12 mg/dl symptomatic hypercalcemia treatment ineligible . 9 . Patients osseous metastasis site disease . 10 . Patients concurrent active malignancy nonmelanoma skin cancer carcinomainsitu cervix . Patients previous malignancy without evidence disease &gt; 5 year allow enter trial . 11 . Patients know Gilbert 's syndrome ineligible .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Gastrointestinal cancer</keyword>
	<keyword>high grade gastrointestinal neuroendocrine carcinoma</keyword>
	<keyword>High grade neuroendocrine carcinoma unknown primary site</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Platinol-AQ</keyword>
	<keyword>Platinol</keyword>
	<keyword>CDDP</keyword>
	<keyword>CPT-11</keyword>
	<keyword>Irinotecan</keyword>
</DOC>